Chiesi Global Rare Diseases to Unveil Second Edition of Find For Rare at 2026 ERA Congress
Chiesi Global Rare Diseases to Launch the Second Edition of Find For Rare at 2026 ERA Congress to Advance Research in Lysosomal Storage Disorders
Benzinga
Image: Benzinga
Chiesi Global Rare Diseases will participate in the 63rd European Renal Association Congress from June 3-6, 2026, in Glasgow, Scotland, where it will launch the second edition of Find For Rare. This initiative supports research in lysosomal storage disorders, including Fabry disease and nephropathic cystinosis, aiming to enhance disease understanding and patient care.
- 01Chiesi Global Rare Diseases will launch the second edition of Find For Rare at the ERA Congress, focusing on Fabry disease, alpha-mannosidosis, and nephropathic cystinosis.
- 02The initiative aims to provide funding for innovative research projects to improve understanding and management of lysosomal storage disorders.
- 03Chiesi's contributions at the congress will emphasize real-world clinical outcomes and treatment tolerability in Fabry disease.
- 04Nephropathic cystinosis affects approximately 2,000 patients globally, with early treatment critical to prevent severe complications.
- 05Chiesi Group is committed to advancing rare disease research and aims to achieve net-zero greenhouse gas emissions by 2035.
Advertisement
In-Article Ad
Chiesi Global Rare Diseases, a unit of the Chiesi Group, is set to participate in the 63rd European Renal Association (ERA) Congress from June 3-6, 2026, in Glasgow, Scotland. At this event, the company will launch the second edition of Find For Rare, a research grant initiative aimed at supporting innovative studies in lysosomal storage disorders (LSDs) such as Fabry disease, alpha-mannosidosis, and nephropathic cystinosis. Through this initiative, Chiesi seeks to enhance scientific understanding and improve patient care for these rare conditions. The congress will also feature discussions on clinical outcomes and treatment tolerability for Fabry disease and nephrology-led care strategies for nephropathic cystinosis. This commitment to advancing research aims to create a lasting impact on the rare disease community. Chiesi's efforts reflect a broader mission to ensure equal access to therapies for rare diseases and contribute to environmental sustainability, with a goal of achieving net-zero greenhouse gas emissions by 2035.
Advertisement
In-Article Ad
The initiative aims to improve research and treatment options for patients with rare diseases, particularly those affected by lysosomal storage disorders.
Advertisement
In-Article Ad
Reader Poll
What do you think about the importance of research in rare diseases?
Connecting to poll...
Read the original article
Visit the source for the complete story.